Supplementary Methods, Tables 1 - 2 from Neoadjuvant Imatinib in Advanced Primary or Locally Recurrent Dermatofibrosarcoma Protuberans: A Multicenter Phase II DeCOG Trial with Long-term Follow-up

Abstract

PDF file - 98K, Table 1. Toxicity of the intention to treat (ITT) population, classified and graded according to CTC 2.0 (http://ctep.cancer.gov/reporting/ctc.html). Data represent the worst CTC grade experienced by each patient. Table 2. Morphological and molecular tumor characteristics as analyzed in the per protocol (PP) population, for details see Patients and Methods. PDGFRB, platelet-derived growth factor receptor beta; EGFR, epidermal growth factor receptor; IR, insulin receptor; NA, not applicable.